The students pulled up to different lanes organized for them to do self-administered tests in their vehicles.
The tests were at no-cost to the students and they were scheduled in advance.
It s a necessary step for Neumann University to offer in-person learning in the spring semester.
MOVE IN DAY: Students at @NeumannUniv have to make One very important stop before moving into the dorms. The campus has partnered with @FlowDiag for a Mobile testing lab. #COVID results for students in 60 minutes. @6abcpic.twitter.com/JUIOsOJ20a TaRhonda Thomas (@TaRhondaThomas) January 15, 2021 Any student who is living on campus must show a negative COVID test before they can arrive and live on campus, said Dr. Chris Domes, Neumann University s President.
(1)
SANTA CLARA, Calif., Jan. 14, 2021 /PRNewswire/ SML Genetree announced today that it has received Emergency Use Authorization (EUA) from the U.S. FDA for the use of its Ezplex SARS-CoV-2 G Kit, a molecular diagnostic test for the qualitative detection of RNA from SARS-CoV-2 from nasopharyngeal swabs, oropharyngeal swabs and sputum specimens as well as for use in pooled patient specimens containing up to 5 upper respiratory swab specimens. Specimens are to be collected by a healthcare provider using individual vials containing transport media.
Sample pooling is an important public health tool because it allows for more people to be tested quickly using fewer testing resources. Pooled testing is most efficient in areas with low prevalence, meaning most results are expected to be negative. By providing a pooling protocol, we can assist laboratories in meeting the demand for accurate, high volume molecular test results, said SML Genetree s CEO, Mr. Jihoon Ahn. We are excited t
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing
News provided by
Share this article
SAN CARLOS, Calif., Jan. 14, 2021 /PRNewswire/
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on the Prospera test at the American Society of Transplant Surgeons (ASTS) 21st Annual Winter Symposium, taking place January 14-16, 2021.
Natera will present five posters, featuring case studies that detail the use of the Prospera test to detect active rejection and injury of kidney transplants. Donor-derived cfDNA testing is becoming an increasingly powerful tool to better assess kidney transplant rejection, and I m delighted to collaborate with Natera, who is at the forefront of this research, said Dr. Obi Ekwenna, MD, FACS, Transplant Surgeon at the University of Toledo Medical Center, and first author of two of the studies to be presented. In our studies, we sho
By Sulli (not verified) on 18 Apr 2016 #permalink
It would ve been nice if the integrative functional care team had assigned this patient a Pill Administrator so she had help in managing her zillion drugs and supplements. Or maybe they gave her a giant-size compartmentalized Pill Wheel so she knew what and when to take every day.
I have a hard time believing all of the added functional sludge they gave her helped her gastritis issues or contributed in any way to quality of life, much less her remission from cancer. At least they didn t prescribe twice daily coffee enemas like those poor patients with pancreatic cancer treated by Nicholas Gonzalez.
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment
News provided by
Share this article
SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology s 2021 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 15-17, 2021.
Natera will have one oral and one poster presentation, each describing the clinical performance of Signatera in patients with colorectal cancer (CRC).